2 registrations that name lactobacillus crispatus as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT07308808
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
Early phase 1
Medstar Health Research Institute
About 40 people
Started Sep 9, 2025
In plain words An early phase 1 study of lactobacillus crispatus in people 18 and older, run by Medstar Health Research Institute. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Spinal Cord Injuries (SCI); Neurogenic Bladder; Urinary Tract Infection (Diagnosis).
Age ≥ 18 years
SCI with at least 6-month duration
NLUTD
Utilizing intermittent catheterization for bladder management
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Lactobacillus Crispatus; Saline bladder wash
Registered summary
The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\[s\] it aims to answer are: 1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07474831
Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis
No phase
Liaquat University of Medical & Health Sciences
About 132 people
Started Mar 23, 2026
In plain words A study of lactobacillus crispatus in female participants 18 to 45, run by Liaquat University of Medical & Health Sciences. It plans to enroll about 132 people at 11 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Recurrent Bacterial Vaginosis.
Women aged 18-45 years
Diagnosis of recurrent bacterial vaginosis (≥3 episodes of bacterial vaginosis within 12 months prior to enrollment)
Presence of a diagnosis of bacterial vaginosis at the time of enrollment, carried out through the presence of 3 out of 4 of the Amsel Criteria
Accepted written informed consent for study participation obtained prior to the start of the study
The exclusion criteria are on the listing.
What it tests, as registered
Lactobacillus crispatus CRP21; Placebo
Registered summary
Recurrent bacterial vaginosis is a common condition in women of reproductive age and is characterized by a disruption of the normal vaginal microbiota, with a reduction in Lactobacillus species and an overgrowth of anaerobic bacteria such as Gardnerella vaginalis. Recurrence rates after standard antibiotic treatment are high. Lactobacillus crispatus is considered one of the most protective species for maintaining vaginal microbiota balance. The full summary is on the listing.
Where, as registered
No US site; Italy (11).
ClinicalTrials.gov lists 5 open registrations for this search, including ones where lactobacillus crispatus is not a study arm or that are past the 2 we keep. Search them on ClinicalTrials.gov (opens in new tab).